Navigation Links
Duragesic Trials Continue - Plaintiffs Optimistic After Latest Recall
Date:2/13/2008

Lawyer who brought the first federal case against J&J prepares for next

trial

LOS ANGELES, Feb. 13 /PRNewswire/ -- In the wake of Tuesday's Duragesic recall of over 2 million patches, lawyer Ike Gulas prepares to take the next major case against pharmaceutical giant Johnson and Johnson to trial in California State Court Southeast District in Los Angeles.

The Birmingham, Ala.-based law firm Gulas & Stuckey PC took the first Duragesic case to federal trial in West Palm Beach in June 2007, winning a $5.5 million verdict for the family of Adam Hendelson who died from an overdose of the drug fentanyl when the patch he wore due to chronic hip pain leaked.

The family of Carol Pinedo will be the second of Gulas & Stuckey's clients to face Johnson & Johnson subsidiaries Janssen Pharmaceutica Products, LP, and ALZA Corp. in court over death resulting from the company's pain patch Duragesic.

Pinedo died in April 2004, the same month Janssen issued a recall of about 2.2 million patches after determining that some might leak along one edge. She was 39 at the time and had been wearing a Duragesic patch for 6 months as treatment for severe migraines following the removal of benign brain tumors.

Pinedo's husband Joseph, has brought the suit forward to Gulas & Stuckey after his wife's death. Joseph is a custodian for the Los Angeles school system with four children: Jessie Marie, Michelle, Christine and Natalie Angela.

"The manufacturers of this drug should be held accountable," said Ike Gulas. "This recent recall reaffirms the fact that this drug is lethal and is responsible for many unnecessary deaths, as in the case of Carol Pinedo."

More than 100 cases have been filed nationwide involving Duragesic. Gulas & Stuckey will take the Pinedo case to trial sometime later this year.

For more information about Duragesic and about Gulas & Stuckey, P.C., go to http://www.gulasandstuckey.com/PracticeAreas/duragesic.asp.


'/>"/>
SOURCE Gulas & Stuckey, P.C.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. PriCara(TM) Recalls 25 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches
2. Study Questions Dead-End Cancer Clinical Trials
3. Clinical trials present better alternatives for dialysis patients
4. IMPACT initiative looks to improve patient participation in clinical trials
5. Clinical Trials Directive still hampering academic medical research
6. Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials
7. American Pacific Management to Present at CIBC World Markets 2nd Industrials Conference
8. Clinical Trials for Lupus Underway After Decades of Drought
9. Paving the way for future pan-European clinical trials
10. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
11. Rutgers biomaterial debuts in clinical trials of new stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... New York (PRWEB) , ... January 16, 2017 ... ... SightMD today announced the addition of Victor Giamos, MD to their ... of SightMD and Managing Partner at North Shore Eye Care, a division of ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol ... protocols to understand the scope of their EHS regulatory obligations and rapidly collect, ...
(Date:1/16/2017)... ... ... St. Louisans are well-aware of the following facts at present:, ... be having no effect on keeping this particularly bad strain of the flu away , ... sneezing, or sniffling , These facts are well-known among the team at ...
(Date:1/16/2017)... Beverly Hills, CA (PRWEB) , ... January 16, ... ... published a manuscript in the Aesthetic Surgery Journal , the official journal ... study he conducted on lower eyelid retraction surgery. The procedure is designed to ...
(Date:1/16/2017)... ... January 16, 2017 , ... One thing common to all types ... to test for, as well. The money spent screening for and treating cancer in ... U.S. screen patients for cancer more than in any other country that has an ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... , January 13, 2017 This ... see how they have fared at yesterday,s closing bell: ... Biopharma Inc. (NASDAQ: GALE ), and ACADIA ... harness cellular and biomolecular processes to develop technologies and ... environmental footprint, feed the hungry, use less and cleaner ...
(Date:1/13/2017)... 2017 The 2016 election resulted in ... states voting in favor of legalizing cannabis for recreational use, ... in the U.S. In addition, the state of ... cannabis products sales. The ArcView Group has published an updated ... cannabis sales in the U.S. last year reached $6.7 billion, a ...
(Date:1/13/2017)... 2017   JDRF , the leading global ... pleased to announce that after more than a ... & Medicaid Services (CMS) has recognized continuous glucose ... use in making diabetes treatment decisions as durable ... eligible for coverage under Medicare. JDRF has been ...
Breaking Medicine Technology: